<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175435</url>
  </required_header>
  <id_info>
    <org_study_id>C05-0027</org_study_id>
    <nct_id>NCT00175435</nct_id>
  </id_info>
  <brief_title>Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator</brief_title>
  <official_title>Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at what happens to the level of protection against hepatitis B (HB)
      disease if a 'helper' gel is applied to the skin over the injection site of a small dose of
      hepatitis B vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A single application of an immune modulating gel will enhance the protective response against hepatitis B disease when vaccination is given at the same time as gel as evidenced by increased HB antibody and T-cell response.</measure>
    <time_frame>at 30 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal adverse effects to gel application as noted by laboratory assessment of liver enzyme and complete blood count (CBC) and physical assessment of the site/surrounding area and solicited local and general post vaccine events.</measure>
    <time_frame>at 7 and 30 days post vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Resiquimod gel</intervention_name>
    <description>3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator</description>
    <arm_group_label>1</arm_group_label>
    <other_name>HPV vaccine - Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Resiquimod gel</intervention_name>
    <description>3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>HPV vaccine = Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Resiquimod gel</intervention_name>
    <description>3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>HPV vaccine = Gardasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously vaccinated with conventional hepatitis B vaccine series 10 or more years
             ago

          -  Generally healthy

          -  Is and has been free of HB disease and/or is negative to core antibody

          -  Known to have sero-converted to positive after vaccine series (without extra doses)

          -  Speaks and understands English adequately

          -  Available for all 4 visits within the designated timelines (30 days)

          -  No allergies to HB vaccine or components

          -  No blood or blood components within previous 6 months

          -  Not pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Dutz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital Vaccine Education Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>October 29, 2010</last_update_submitted>
  <last_update_submitted_qc>October 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jan Dutz</name_title>
    <organization>University of British Columbia</organization>
  </responsible_party>
  <keyword>Topical Immune Modulator</keyword>
  <keyword>resiquimod gel</keyword>
  <keyword>Hepatitis B booster response</keyword>
  <keyword>Vaccine Evaluation</keyword>
  <keyword>Prevention of Hepatitis B disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

